HELICOBACTER PYLORI VA ROSACEA O‘RTASIDAGI BOG‘LIQLIK

Ozoda Ismailova; Shaxnoza Yusupova

Mualliflar

Ozoda Ismailova Dermatovenerologiya yo‘nalishi magistranti Urganch davlat tibbiyot instituti, Urganch, O‘zbekiston ##default.groups.name.author##
Shaxnoza Yusupova Ichki kasalliklar va dermatovenerologiya kafedrasi Katta o‘qituvchisi, PhD. Urganch davlat tibbiyot instituti, Urganch, O‘zbekiston ##default.groups.name.author##

Kalit so‘zlar:

rosacea, Helicobacter pylori, papulopustulyoz rosacea, eritema, eradikatsiya terapiyasi

Abstrak

Rosacea — yuz terisining surunkali yallig‘lanishli dermatozi bo‘lib, eritema, papula, pustula, telangiektaziya, achishish, kuydiruvchi sezgi va ayrim holatlarda ko‘z zararlanishi bilan namoyon bo‘ladi. Kasallik patogenezi ko‘p omilli bo‘lib, unda tug‘ma immunitetning buzilishi, neyrovaskulyar regulyatsiya o‘zgarishlari, teri mikrobiotasi disbalansi, Demodex spp. kolonizatsiyasi, ultrabinafsha nurlanish, stress, oziq-ovqat triggerlari va gastrointestinal omillar muhim o‘rin tutadi. So‘nggi yillarda Helicobacter pylori infeksiyasining rosacea rivojlanishi va klinik kechishidagi ehtimoliy roli keng muhokama qilinmoqda. H. pylori oshqozon shilliq qavatida yashovchi gram-manfiy spiral bakteriya bo‘lib, gastrit, peptik yara kasalligi va ayrim malign jarayonlar bilan bog‘liq. Bir qator tadqiqotlarda rosaceali bemorlarda H. pylori infeksiyasi ko‘proq uchrashi, eradikatsiya terapiyasidan so‘ng papulopustulyoz elementlar va eritema kamayishi mumkinligi qayd etilgan. Biroq barcha tadqiqotlar ham bu bog‘liqlikni tasdiqlamaydi. Shu sababli H. pylori rosaceaning yagona etiologik sababi sifatida emas, balki ayrim bemorlarda kasallikni kuchaytiruvchi trigger yoki komorbid omil sifatida baholanishi maqsadga muvofiqdir. Ushbu maqolada H. pylori va rosacea o‘rtasidagi patogenetik mexanizmlar, klinik-epidemiologik ma’lumotlar, diagnostik yondashuvlar hamda davolashdagi ahamiyati tahlil qilinadi.

##plugins.themes.default.displayStats.downloads##

##plugins.themes.default.displayStats.noStats##

Havolalar

1. Gao Y, Yang XJ, Zhu Y, Yang M, Gu F. Association between rosacea and Helicobacter pylori infection: A meta-analysis. PLoS One. 2024;19(4):e0301703. doi:10.1371/journal.pone.0301703.

2. Jørgensen AR, Egeberg A, Gideonsson R, Weinstock LB, Thyssen EP, Thyssen JP. Rosacea is associated with Helicobacter pylori: a systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology. 2017;31(12):2010–2015.

3. Gallo RL, Granstein RD, Kang S, Mannis M, Steinhoff M, Tan J, Thiboutot D. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee. Journal of the American Academy of Dermatology. 2018;78(1):148–155. doi:10.1016/j.jaad.2017.08.037.

4. Thiboutot D, Anderson R, Cook-Bolden F, Draelos Z, Gallo RL, Granstein RD, Kang S, Macsai M, Gold LS, Tan J. Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee. Journal of the American Academy of Dermatology. 2020;82(6):1501–1510. doi:10.1016/j.jaad.2020.01.077.

5. Schaller M, Almeida LMC, Bewley A, et al. Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. British Journal of Dermatology. 2020;182(5):1269–1276. doi:10.1111/bjd.18420.

6. van Zuuren EJ. Rosacea. New England Journal of Medicine. 2017;377(18):1754–1764.

7. Nguyen C, Kuceki G, Birdsall M, Sahni DR, Sahni VN, Hull CM. Rosacea: Practical Guidance and Challenges for Clinical Management. Clinical, Cosmetic and Investigational Dermatology. 2024;17:175–190. doi:10.2147/CCID.S391705.

8. Yang F, Wang L, Song D, Zhang L, Wang X, Du D, Jiang X. Signaling pathways and targeted therapy for rosacea. Frontiers in Immunology. 2024;15:1367994. doi:10.3389/fimmu.2024.1367994.

9. Tu KY, Jung CJ, Shih YH, Chang ALS. Therapeutic strategies focusing on immune dysregulation and neuroinflammation in rosacea. Frontiers in Immunology. 2024;15:1403798. doi:10.3389/fimmu.2024.1403798.

10. Zhu W, Hamblin MR, Wen X. Role of the skin microbiota and intestinal microbiome in rosacea. Frontiers in Microbiology. 2023;14:1108661.

11. Yang X. Relationship between Helicobacter pylori and Rosacea: review and discussion. BMC Infectious Diseases. 2018;18(1):318.

12. Chey WD, Howden CW, Moss SF, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. American Journal of Gastroenterology. 2024;119:1730–1753.

13. Bamford JTM, Tilden RL, Blankush JL, Gangeness DE. Effect of treatment of Helicobacter pylori infection on rosacea. Archives of Dermatology. 1999;135(6):659–663.

14. Diaz C, O’Callaghan CJ, Khan A, Ilchyshyn A. Rosacea: a cutaneous marker of Helicobacter pylori infection? Results of a pilot study. Acta Dermato-Venereologica. 2003;83(4):282–286.

15. Guarneri C, Ceccarelli M, Rinaldi L, et al. Helicobacter pylori and skin disorders: a comprehensive review of the available literature. European Review for Medical and Pharmacological Sciences. 2020;24(23):12267–12287.